… The coprimary efficacy objectives of this study are … will provide a new alternative third-line
treatment option for patients with … with advanced NSCLC and found no significant difference in …

… (FDA) as a third-line treatment for lung cancer based on improved … the efficacy and tolerability
of gefitinib in treating EGFR … Gefitinib and erlotinib have not been compared directly in …

… This study compared the efficacy and toxicity of osimertinib … as the third-line therapy in
patients with local advanced or … in treatment of NSCLC after resistant to gefitinib or erlotinib was …

… trial compared erlotinib alone (150 mg/day) versus erlotinib at … Erlotinib is registered worldwide
for second- and third-line … testing the efficacy of intercalated EGFR-TKI and chemotherapy …

… the efficacy and tolerability of first-line treatment with erlotinib … (1–26 months) compared to
the overall 24 months median … -line therapy, nine (31%) received also a third-line and three (…

… compared with single-agent chemotherapy in patients who acquired resistance to
erlotinib/gefitinib … afatinib in a greater than or equal to third-line setting, ≥12 weeks of disease …

… Moreover, in a head-to-head comparison afatinib improved efficacy versus gefitinib in … with
chemotherapy. When dacomitinib was compared with erlotinib as second-/third-line treatment …

… -line treatment for advanced non-small-cell lung cancer (… treatment. Some clinical trials and
meta-analyses investigated the … the efficacy of EGFR-TKIs (erlotinib or gefitinib) compared to …

… to compare combination treatment with bevacizumab and … with second-line or third-line
monotherapy.8 Furthermore, Erl … other six different treatments, including Erl, gefitinib, cetuximab, …

… , open-label, phase III study to compare the efficacy and safety of the EGFR-TKI G versus …
received erlotinib as second-line therapy followed by gefitinib re-challenge as third-line therapy)…